NANOTECHNOLOGY: A PATHWAY FOR SUSTAINABLE INNOVATION IN DRUG DEVELOPMENT

[vc_row][vc_column][vc_column_text]Here, Andrea Cusack, Chief Executive Officer, leon, discusses how, by using bottom-up nanotechnology techniques, efficiencies can be found both in the development of new chemical entities and in the repurposing of existing drugs, and how these efficiencies translate into reduced energy requirements and therefore more sustainable industry practices.[/vc_column_text][vc_separator sep_color=”” uncode_shortcode_id=”284518″][vc_custom_heading heading_semantic=”h3″ text_size=”h3″ uncode_shortcode_id=”124387″]Related Files[/vc_custom_heading][vc_icon position=”left” space_reduced=”yes” icon=”fa fa-file-pdf-o” icon_color=”color-cerise” background_style=”fa-squared” uncode_shortcode_id=”777600″ icon_color_type=”uncode-palette”]FF0040_ODD_Sep-Oct_2020__112__Leon_JA_v3_PW_comments_AC_rev_IK[/vc_icon][/vc_column][/vc_row]

About LEON

Based in Planegg/Munich, leon-nanodrugs GmbH is a pharmatech company specializing in the development and commercialization of equipment for the encapsulation of genetic material and other pharmaceutical active substances into nanoparticles, such as lipid nanoparticles (LNPs).

The company leverages its proprietary FR-JET®  technology to build innovative solutions. Its equipment portfolio includes NANOscreen® for formulation screening, NANOlab® for process development, as well as NANOme® and NANOus® for GMP manufacture. These systems are suitable for both individualized scales and commercial production, and the company further supports its clients by offering formulation and process development services.

LEON’s platform aims to empower pharmaceutical companies, small biotech, research institutes, and CDMOs to capitalize on advancements in advanced therapies.

For general information and enquiries please email info@leon-nanodrugs.com